Multiple Myeloma

A subgroup analysis of the FORTE study found that carfilzomib-lenalidomide-dexamethasone induction/consolidation (KRd) plus ASCT and carfilzomib-lenalidomide maintenance provided survival benefit to patients of all cytogenetic risk groups, including patients at high risk. Read More ›

Findings of the multicohort phase 1 TRIMM-2 trial showed that the G-protein–coupled receptor family C group 5 member D x CD3 bispecific antibody talqueta­mab in combination with daratumumab therapy was well-tolerated and resulted in promising antitumor activity in patients with RRMM, supporting further evaluation of this combination. Read More ›

For this supplement, the expert faculty provided detailed perspectives based on their extensive experience with the management of cancer patients with bone involvement, especially skeletal-related events associated with solid tumor metastases and lytic lesions due to multiple myeloma. Read More ›

A post-hoc analysis of a pivotal clinical trial showed that belantamab mafodotin-blmf (Blenrep), a first-in-class antibody–drug conjugate targeting B-cell maturation antigen, induced deep and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Read More ›

IKEMA is an ongoing, phase 3, randomized, open-label, parallel-group study that reached its interim analysis milestone. The study evaluated the effect of adding isatuximab (Isa) to carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

In patients with relapsed/refractory multiple myeloma (RRMM) at target dose levels of ≥150 × 10⁶ chimeric antigen receptor (CAR)+ T-cells, the updated analysis of the phase 1 CRB-401 study supports a favorable clinical benefit–risk profile for the B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, idecabtagene vicleucel. Read More ›

In heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), preliminary results from the phase 1b/2 CARTITUDE-1 study show early, deep, and durable responses with a single low-dose infusion of ciltacabtagene autoleucel (cilta-cel) and a safety profile consistent with prior studies. Read More ›

Favorable efficacy and manageable safety are shown in the updated analysis of the phase 1 study of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM). This analysis supports the planned phase 2 monotherapy trial at 1500 µg/kg administered subcutaneously. Read More ›

This phase 1, first-in-human study evaluates patients with relapsed/refractory multiple myeloma (RRMM) who are heavily pretreated with REGN5458. Results of this updated analysis are consistent with those of previous findings showing an acceptable safety profile and deep and durable responses. The phase 2 portion of the study is further progressing. Read More ›

This primary analysis evaluated patients with relapsed/refractory multiple myeloma (RRMM) who had received ≥1 prior lines of therapy, including lenalidomide (Len) and a proteasome inhibitor (PI). Compared with pomalidomide and dexamethasone (Pd) alone, daratumumab (DARA) plus Pd reduced the risk of disease progression and death without additional safety signals. Read More ›